WP3
DFIL2
Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes
IL-2 is an inducer of regulatory T cells (Treg), a population of lymphocytes that fail to control the autoimmune destruction of beta-cells in patients with Type 1 D...
IL-2 is an inducer of regulatory T cells (Treg), a population of lymphocytes that fail to control the autoimmune destruction of beta-cells in patients with Type 1 D...
WP3
DIABIL2
European phase-II
clinical trial evaluating efficacy of low dose rhIL-2 in patients with
recently-diagnosed type 1 diabetes
Clinical and preclinical studies, together with supportive mechanistic da...
Clinical and preclinical studies, together with supportive mechanistic da...
WP3
TRANSREG
TRANSREG is a multicentric, uncontrolled, open-label study, comparing biological and clinical responses to the administration of low dose of IL-2 across 11 selected pathologies (12 patients/pathology): rheumatoid arthritis, ankylosing spondyliti...
WP3
Impact Crohn
Impact of the Fecal Flora Transplantation on Crohn's DiseaseCrohn's disease is a chronic and relapsing inflammatory bowel disease. Many data show that the intestinal flora is involved in the disease and it has been show t...
WP3
MSIL2
Biological activity and safety of low dose IL2 in Relapsing Remitting Multiple Sclerosis
Interleukin‐2 (IL‐2) was initially discovered and used as a stimulator of effector T lymphocytes (Teffs), but is now viewed as a very promising...
Interleukin‐2 (IL‐2) was initially discovered and used as a stimulator of effector T lymphocytes (Teffs), but is now viewed as a very promising...